Literature DB >> 2807277

Two distinct variants of erythrocyte spectrin beta IV domain.

B Pothier1, N Alloisio, L Morlé, J Maréchal, H Barthélemy, M T Ducluzeau, A Dorier, J Delaunay.   

Abstract

We report two distinct variants affecting the beta IV domain of erythrocyte spectrin, designated spectrin Saint-Chamond and spectrin Tlemcen. They were discovered in a French family and an Algerian individual, respectively. They appeared clinically and morphologically asymptomatic in the heterozygous state. In two-dimensional maps of spectrin partial digests, both mutants were manifested by cathodic shifts (with no change of the molecular weights) of the peptides that cover the N-terminal region of spectrin beta IV domain. The relevance of the abnormal peptides to the beta IV domain was established by quantitative analysis and by Western blotting using anti-beta IV domain-specific antibodies. These two variants are thus far the most distal variants of spectrin to be defined on an unequivocal structural basis.

Mesh:

Substances:

Year:  1989        PMID: 2807277     DOI: 10.1007/bf00291384

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  13 in total

Review 1.  Hereditary elliptocytosis, spherocytosis and related disorders: consequences of a deficiency or a mutation of membrane skeletal proteins.

Authors:  J Palek
Journal:  Blood Rev       Date:  1987-09       Impact factor: 8.250

2.  Spectrin Nice (beta 220/216): a shortened beta-chain variant associated with an increase of the alpha I/74 fragment in a case of elliptocytosis.

Authors:  B Pothier; L Morlé; N Alloisio; M T Ducluzeau; C Caldani; C Féo; M Garbarz; I Chaveroche; D Dhermy; M C Lecomte
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

3.  Isolation of the chemical domains of human erythrocyte spectrin.

Authors:  W J Knowles; M L Bologna
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

4.  A genetic defect in the binding of protein 4.1 to spectrin in a kindred with hereditary spherocytosis.

Authors:  L C Wolfe; K M John; J C Falcone; A M Byrne; S E Lux
Journal:  N Engl J Med       Date:  1982-11-25       Impact factor: 91.245

5.  Elution of proteins from sodium dodecyl sulfate-polyacrylamide gels, removal of sodium dodecyl sulfate, and renaturation of enzymatic activity: results with sigma subunit of Escherichia coli RNA polymerase, wheat germ DNA topoisomerase, and other enzymes.

Authors:  D A Hager; R R Burgess
Journal:  Anal Biochem       Date:  1980-11-15       Impact factor: 3.365

Review 6.  Spectrin: structure, function, and abnormalities.

Authors:  W Knowles; S L Marchesi; V T Marchesi
Journal:  Semin Hematol       Date:  1983-07       Impact factor: 3.851

7.  A structural model of human erythrocyte spectrin. Alignment of chemical and functional domains.

Authors:  D W Speicher; J S Morrow; W J Knowles; V T Marchesi
Journal:  J Biol Chem       Date:  1982-08-10       Impact factor: 5.157

8.  Erythrocyte spectrin is comprised of many homologous triple helical segments.

Authors:  D W Speicher; V T Marchesi
Journal:  Nature       Date:  1984 Sep 13-19       Impact factor: 49.962

9.  Spectrin Oran (alpha II/21), a new spectrin variant concerning the alpha II domain and causing severe elliptocytosis in the homozygous state.

Authors:  N Alloisio; L Morlé; B Pothier; A F Roux; J Maréchal; M T Ducluzeau; Z Benhadji-Zouaoui; J Delaunay
Journal:  Blood       Date:  1988-04       Impact factor: 22.113

10.  Visualization of the hexagonal lattice in the erythrocyte membrane skeleton.

Authors:  S C Liu; L H Derick; J Palek
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

View more
  1 in total

1.  Sp alpha V/41: a common spectrin polymorphism at the alpha IV-alpha V domain junction. Relevance to the expression level of hereditary elliptocytosis due to alpha-spectrin variants located in trans.

Authors:  N Alloisio; L Morlé; J Maréchal; A F Roux; M T Ducluzeau; D Guetarni; B Pothier; F Baklouti; A Ghanem; R Kastally; J Delaunay
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.